Ernesto Estrada, Samuel Vazquez, Jul 28, 2013
This document studies bid rigging in public procurement of generic drugs in Mexico. The study is based on the outcomes of a series of public auctions for generic drugs held in 52 different locations between 2003 and 2008. By applying price and market share screenings, we identify many drugs where lowest bids tend to be identical across auctions regardless of winner, location or contract volume; and market shares quickly converge over time. Additionally, bids dropped and the above pattern disappeared after aggressive entry or procurement consolidation occurred. These findings triggered a formal investigation by the Mexican antitrust agency of two of the largest families of drugs: insulin and saline solutions. These collusive patterns and other indirect evidence gathered during the investigation, led to issue a decision by the agency of illegal bid rigging in both cases. This decision was challenged before Mexican courts, which confirmed it.
Featured News
Judge Pushes Elite College Financial Aid Antitrust Trial Toward Thanksgiving Finish
Jul 23, 2026 by
CPI
Altria, Juul Ask Appeals Court to Reverse Antitrust Class Certification
Jul 23, 2026 by
CPI
Japan Expands Antitrust Watchdog’s Role With New Bureau for Big Tech Oversight
Jul 23, 2026 by
CPI
DOJ Introduces Faster Merger Review Process With Targeted Antitrust Requests
Jul 23, 2026 by
CPI
EU Hits Google With $1 Billion Fine in First Digital Markets Act Penalty
Jul 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes